Ballicules.com

Droperidol

INAPSINE

What it isButyrophenone D2 antagonist used parenterally for severe nausea, acute agitation, and perioperative sedation.

Why this oneRapid, reliable control of agitation and refractory emesis in small IM or IV doses.

What limits itQT prolongation, hypotension, and extrapyramidal reactions constrain use; screen for QT risk and monitor when indicated.

FDA-approved for

Off-label

FDA label

BOXED WARNING QT prolongation/torsade de pointes reported at or below recommended doses, some fatal; reserve for patients failing other treatments; 12-lead ECG before use.
FDA dosingPopulationStartTargetMax
Perioperative nausea/vomiting (refractory)Adults2.5 mg IM or slow IVAdditional 1.25 mg PRN
Perioperative nausea/vomiting (refractory)Children 2-12 yr0.1 mg/kg IM or IV (max initial)0.1 mg/kg initial

Renal Undefined

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Pregnancy Category C; use only if potential benefit justifies risk to fetus.

Lactation Undefined

⚠ BOXED WARNINGS

Cost, est. cash$20–$1,500/dose or month

Generic entry1986

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability1 / 4
Sedation liability1 / 4
QT / Torsades4 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityMetabolic effects, extrapyramidal symptoms/tardive dyskinesia and agent-specific QT or orthostatic risk.

Mechanism of action: Droperidol ballicule

Droperidol ballicule: receptor binding, kinetics and half-life diagram

Open Droperidol in the interactive console ↗

Memory aids: mascots and interaction avatars

Droperidol INAPSINE mascot mnemonic cartoon
“Drop a doll In a scene”
spooky mascot → antipsychotic
greyscale → high potency first-gen antipsychotic
rainbow spray → antiemetic
Droperidol CYP3A4 substrate avatar
CYP3A4 substrate

Open Droperidol in the interactive console ↗